Wakamoat Pharmaceutical Issues FY Dividend Plan at Y3.00

Wakamoto Pharmaceutical Co. Ltd. (4512.TO) PARENT Latest Revision Previous For Year to Mar 2024 Plan Year-end Y3.00 N/A Annual Y3.00

Dow JonesMar 22 14:00

Wakamoto Pharmaceutical Sees FY Parent Pretax Loss Y80.00M

PARENT New Forecast For Year to Mar 2024 Revenue Y7.80 bln Operating Profit (Y120.00 mln) Pretax Profit (Y80.00 mln)

Dow JonesFeb 5 14:00

Wakamoto Pharmaceutical 1H Parent Loss Y222.00M Vs Loss Y21.00M

Wakamoto Pharmaceutical Co. Ltd. (4512.TO) Japan 1st Half Ended September 30 PARENT 2023 2022 Revenue Y3.62 bln Y4.02 bln Operating Pro

Dow JonesNov 6, 2023 14:01

Wakamoto Pharmaceutical 1Q Parent Net Y100.00M Vs Loss Y4.00M

Wakamoto Pharmaceutical Co. Ltd. (4512.TO) Japan 1st Quarter Ended June 30 PARENT 2023 2022 Revenue Y1.86 bln Y2.02 bln Operating Profit

Dow JonesAug 4, 2023 14:02

Wakamoto Pharmaceutical FY Parent Net Y138.00M Vs Net Y238.00M

Wakamoto Pharmaceutical Co. Ltd. (4512.TO) Japan Year Ended March 31 PARENT 2023 2022 Revenue Y8.66 bln Y8.38 bln Operating Profit

Dow JonesMay 15, 2023 14:04

Wakamoto Pharmaceutical 9-Mos Parent Net Y110.00M Vs Net Y210.00M

Wakamoto Pharmaceutical Co. Ltd. (4512.TO) Japan Nine Months Ended December 31 PARENT 2022 2021 Revenue Y6.27 bln Y6.27 bln Operating

Dow JonesFeb 2, 2023 14:03